You ask a good question. I believe this is why Dr. Linda Liau comes across strongly on the long tail of survivors. She has seen something that works extremely well for at least a substantial subgroup and perhaps better than SOC for many others as she speaks about the entire group in this particular trial. She knows regulators want to see advancement in the treatment of GBM and are looking for a way to get it. That long tail just by itself would be almost impossible to take a pass on. Best wishes.
News 
Market Data 
Discover 
